Oseltamivir Patent Status
Oseltamivir, the active ingredient in Tamiflu, is no longer protected by its primary patents in many key markets [1]. The original patent for oseltamivir phosphate was filed by Roche in the early 1990s, and these patents have since expired, allowing for the potential development of generic versions [2].
When Did Oseltamivir Patents Expire?
The core patents protecting oseltamivir have expired. For instance, in the United States, the main patent expired around 2014-2015, and in Europe, similar patent expiries occurred around the same period [2]. DrugPatentWatch.com tracks these patent expiry dates for pharmaceuticals [1].
Can Generic Oseltamivir Be Manufactured?
With the expiration of the primary patents, generic manufacturers can now produce and market oseltamivir [1][2]. This typically leads to increased competition and lower prices for the medication.
What Was the Original Patent Holder?
Hoffmann-La Roche, commonly known as Roche, was the original developer and patent holder of oseltamivir phosphate [2].
What is Oseltamivir Used For?
Oseltamivir is an antiviral medication primarily used for the treatment and prevention of influenza A and B virus infections [3]. It works by inhibiting the neuraminidase enzyme, which is essential for the release of new virus particles from infected cells [4].